Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors. (Q36345325)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16361117%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

review article

1 reference

title

Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16361117%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

0 references

0 references

Duchenne muscular dystrophy

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16361117%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

Michael J Blankinship

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16361117%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Jeffrey S Chamberlain

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16361117%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

publication date

19 December 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16361117%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16361117%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16361117%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16361117%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

241-249

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16361117%20AND%20SRC:MED&resulttype=core&format=json

The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein

10 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Clades of Adeno-associated viruses are widely disseminated in human tissues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Differential myocardial gene delivery by recombinant serotype-specific adeno-associated viral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Very mild muscular dystrophy associated with the deletion of 46% of dystrophin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Stable micro-dystrophin gene transfer using an integrating adeno-retroviral hybrid vector ameliorates the dystrophic pathology in mdx mouse muscle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Systemic delivery of genes to striated muscles using adeno-associated viral vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Loss of myostatin attenuates severity of muscular dystrophy in mdx mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Femoral intra-arterial injection: a tool to deliver and assess recombinant AAV constructs in rodents whole hind limb

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Uniform scale-independent gene transfer to striated muscle after transvenular extravasation of vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Global cardiac-specific transgene expression using cardiopulmonary bypass with cardiac isolation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Mutation rates in the dystrophin gene: a hotspot of mutation at a CpG dinucleotide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Revertant fibres: a possible genetic therapy for Duchenne muscular dystrophy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Large-scale analysis of adeno-associated virus vector integration sites in normal human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Genetic fate of recombinant adeno-associated virus vector genomes in muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001

inferred from DOI database lookup

7 January 2021

based on heuristic

Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.001